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The immunomodulatory enzyme indoleamine 2,3-dioxygenase
(IDO) is activated by interferon-c (IFN-c) and via tryptophan
depletion, suppresses adaptive T cell-mediated immunity in
inflammation, host immune defense, and maternal tolerance.
Its role in solid organ transplantation is still unclear. Therefore,
we investigated the usefulness of IDO-mediated tryptophan
catabolism in the evaluation of kidney allograft rejection.
Blood, urine, and tissue samples were collected from 34 renal
transplant patients without rejection and from nine patients
with biopsy-confirmed episodes of acute rejection (n¼ 12).
Concentrations of kynurenine and tryptophan in serum and
urine were analyzed by high-pressure liquid chromatography.
Kynurenine to tryptophan ratio (kyn/trp) was calculated to
estimate IDO activity. Immunostaining for IDO was performed
on renal biopsies. Neopterin was assessed using
radioimmunoassay. Kyn/trp and neopterin were detectable at
low levels in serum of healthy volunteers and were increased
in non-rejecting allograft recipients. Serum levels of kyn/trp
were higher in recipients with rejection compared to
non-rejectors as early as by day 1 post-surgery. Rejection
episodes occurring within 1375.9 days after transplantation
were accompanied by elevated kyn/trp in serum (1147
44.5 lmol/mmol, P¼ 0.001) and urine (126765.9 lmol/mmol,
P¼ 0.02) compared to levels during stable graft function.
Kyn/trp correlated significantly with neopterin suggesting
an IFN-c-induced increase in IDO activity. Immunostaining
showed upregulation of IDO in rejection biopsies, localized in
tubular-epithelial cells. Non-rejected grafts displayed no IDO
expression. Acute rejection is associated with simultaneously
increased serum and urinary kyn/trp in patients after kidney
transplantation. Thus, IDO activity might offer a novel
non-invasive means of immunomonitoring of renal allografts.
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Renal transplantation is currently the treatment of choice for
most patients with end-stage kidney disease. However,
despite continuous advances in immunosuppressive therapy
and prophylaxis of infectious complications, acute rejection
still remains a problem following kidney transplantation.1 To
date, needle biopsy of the graft is the most sensitive and
specific means of diagnosing acute rejection, although there
is a 5–10% risk of biopsy-associated complications, such as
hematuria, hematoma, arteriovenous fistulas, and even graft
loss.2 As no tests are available to accurately and consistently
predict the risk for allograft rejection, the development of less
invasive diagnostic methods that additionally provide
insights into the pathophysiology of rejection would be of
considerable value. As a consequence, immunosuppressive
therapy could be individualized and the adverse effects of
inadequate or overimmunosuppression minimized.3 The
ultimate clinical goal, however, remains donor-antigen-
specific tolerance induction and thus avoidance of any
systemic immunosuppressive treatment.4
Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxy-
genase (IDO) are rate-limiting enzymes in the degradation of
the essential amino acid tryptophan via the kynurenine
pathway to form N-formyl kynurenine, which in the liver is
subsequently converted to niacin. Unlike tryptophan 2,3-
dioxygenase, IDO is widely distributed in mammals and is
induced in various cell types, particularly by the Th1-type
cytokine interferon-g (IFN-g).5 For many years, IDO has
been known as an innate defense mechanism limiting growth
of viruses, bacteria, intracellular pathogens, or malignant cells
by withdrawing tryptophan from the local micro-environ-
ment.6,7 More recently, it has been proposed that activation
of IDO is also critically involved in regulating immune
responses,8 establishing immune tolerance in pregnant mice
upon their fetuses,9 or inducing T-cell unresponsiveness.10
Proliferation of alloreactive T cells is thereby arrested via local
tryptophan deprivation and the accumulation of toxic,
proapoptotic catabolites such as kynurenine and quinolinic
acid.11 Furthermore, IDO serves as a downstream suppressor
mechanism used by T-regulatory cells.12 Despite growing
recognition of the molecular pro-tolerogenic T-cell regula-
tory mechanisms, the physiologic role of IDO in solid organ
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transplantation remains unclear. Available experimental data
indicate that IDO is involved in the mechanism of
spontaneous donor-specific tolerance of liver grafts.13 In
addition, genetic manipulation by adenovirus-mediated
introduction of the IDO gene into pancreatic islet cells is
associated with prolonged graft survival.14 Based on these
findings, the concept that cells expressing IDO can inhibit
T-cell responses and hence induce tolerance has emerged as a
new paradigm in immunology.
The rate of tryptophan degradation expressed by the ratio
of product (kynurenine, kyn) and substrate (tryptophan, trp)
kyn/trp was seen to be a good estimate of biological IDO-
enzyme activity.15,16 Close correlations exist between markers
of immune activation like neopterin and kyn/trp.16,17
Neopterin, a pteridine derivative secreted by monocyte-
derived macrophages upon stimulation with IFN-g, is a
sensitive marker of cellular Th1-type immune responses and
has been shown to predict allograft rejection.18,19
In this study, serum and urine concentrations of
tryptophan, kynurenine, and kyn/trp were analyzed in renal
allograft recipients with stable graft function and during
rejection episodes to determine the usefulness of peripheral
IDO-mediated tryptophan catabolism for non-invasive im-
munomonitoring. Moreover, IDO expression patterns in
renal tissue were also examined by immunohistochemistry.
RESULTS
Patients and clinical follow-up
The clinical characteristics of the patients are summarized in
Table 1. According to their postoperative course, patients
were divided into two groups: Group I: patients with an
immunologically uneventful postoperative course, Group II:
patients who experienced at least one acute rejection episode
in the first 3 weeks. No statistically significant differences
were observed between those groups for age, gender, duration
of cold ischemia, number of human lymphocyte antigen
mismatches, pretransplant creatinine levels, and cytomegalo-
virus match. Forty-two of the patients had received a kidney
from cadaveric donors; one patient had received a graft from
a living related donor. In Group II, we observed 12 acute
rejection episodes in nine patients. Acute rejection occurred
at a mean of 1375.9 days after transplantation. Rejection was
diagnosed by renal biopsy or on clinical judgement based on
the presence of the following criteria: a 0.3 mg/100 ml rise in
serum creatinine, oliguria, or an increased resistance index
and graft swelling at ultrasound examination. In 10 of 12
cases, the diagnosis of acute rejection was confirmed by
histology. Three biopsies were graded type I and seven type II
according to the Banff classification.
As shown in Table 1, all patients in Group II received
immunosuppressive therapy based on calcineurin inhibitors
and prednisone in combination with mycofenolate mofetil.
One patient in this group was treated with basiliximab and
four patients received induction therapy, either with ATG
or Campath-1H. In Group I, 14 patients were treated with
basiliximab, seven with azathioprine, three with rapamycin,
and nine patients received induction therapy. Six patients
experienced infection episodes during the observation
period, four had a herpes simplex infection, one patient
experienced urinary tract infection, and one suffered from
sepsis. However, no complications related to cytomegalovirus
infection or disease were observed in this study population.
Serum tryptophan, kynurenine, and neopterin levels
following renal transplantation
As early as by day one post-transplantation serum kyn/trp,
kynurenine, and neopterin concentrations were significantly
elevated in patients who subsequently had an acute rejection
episode (Group II) as compared with those of Group I, who
had an uncomplicated course after surgery (Figure 1a–d).
Furthermore, these differences in kyn/trp, kynurenine, and
neopterin concentrations remained significant throughout
the entire observation period. Pretransplant levels of
Table 1 | Demographic data and clinical characteristics
of patients
Total Group I Group II
Number of patients (M/F) 43 (30/13) 34 (24/10) 9 (6/3)
Age in years (mean7s.d.) 52.8713.8 50.8713.9 47.979.7
Cause of end-stage renal disease
Glomerulonephritis 12 7 5
Diabetes 9 7 2
Shrunken kidney 4 3 1
Polycystic nephropathy 4 2 2
Alport syndrome 2 2 0
Repeated transplantation
or graft failure
6 4 2
Other 6 6 0
Drug regimen
C 16/43 14/34 2/9
T 27/43 20/34 7/9
P 43/43 34/34 9/9
A 7/43 7/34 0/9
MMF 33/43 24/34 9/9
R 3/43 3/34 0/9
B 15/43 14/34 1/9
I 13/43 9/34 4/9
Deceased donor 42 33 9
Mean duration of cold ischemia (h) 1474.6 1474.8 1473.9
X1 prior transplantations 6 4 2
43 HLA mismatches 18 14 4
CMV mismatch 18 16 2
Number of acute rejection episodes 12 NA 12
Time to first episode of rejection
(mean days post TX7s.d.)
1375.9 NA 1375.9
Biopsy proven 10 NA 10
A, azathioprine; B, basiliximab; C, cyclosporin A; CMV, cytomegalovirus; F, female;
HLA, human leucocyte antigen; I, induction therapy (ATG or campath-1H); M, male;
MMF, mycophenolate mofetil; NA, not applicable; P, prednisone; R, rapamycin;
T, tacrolimus.
Group I: Patients with an uncomplicated postoperative course; Group II: Patients
with at least one acute rejection episode.
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tryptophan, kynurenine, kyn/trp, and neopterin did not
differ between groups.
Significant correlations existed between kyn/trp and kyn-
urenine and neopterin concentrations (kyn/trp vs neopterin:
rs¼ 0.675, Po0.01; kynurenine vs neopterin: rs¼ 0.512,
P¼ 0.001), and tryptophan and neopterin concentrations
correlated inversely (rs¼0.541, Po0.001).
Serum tryptophan, kynurenine, and neopterin levels during
acute rejection
Kyn/trp, neopterin, and kynurenine were detectable at low
levels in serum of healthy volunteers (Table 2). The
concentrations of tryptophan, kynurenine, and kyn/trp found
in the control group thereby agreed well with the concentra-
tions reported earlier.20 As shown in Table 2, kynurenine, kyn/
trp, and neopterin were significantly higher in transplant
recipients having an uncomplicated postoperative course than
in healthy control individuals. An additional significant
increase in all these parameters was measured in serum of
patients at the time of an acute rejection episode. Tryptophan
concentrations were lower in uncomplicated patients than in
healthy controls (Po0.001) and lowest concentrations were
observed during acute rejection (Po0.001; Table 2). These
data indicate that IDO enzyme activity is upregulated after
renal transplantation and is significantly further elevated
during acute rejection episodes.
Six patients in this study had infectious complications
(herpes simplex, n¼ 4; urinary tract infection, n¼ 1; sepsis,
n¼ 1). However, infection episodes were not associated
with significant changes in either kyn/trp, kynurenine, or
tryptophan concentrations (data not shown).
Urine kyn/trp and neopterin during acute rejection
In parallel to serum levels, we determined urine concentra-
tions of neopterin and kyn/trp in our patients at the time
of acute rejection. As shown in Figure 2, both urine
kyn/trp (126765.9 mmol/mmol) and neopterin levels
(5047303 nmol/l) were significantly higher at the time of
acute rejection as compared to samples obtained during
stable graft function (kyn/trp 94.6773.9 mmol/mmol,
P¼ 0.02; neopterin 2797150 nmol/l, Po0.01) from patients
who had an uncomplicated course after transplantation.
Serum creatinine, creatinine clearance, and urinary volume
Mean pretransplant serum (7s.d. ) creatinine concentrations
were not significantly different between patients with an
immunologically uneventful postoperative course (7.957
2.32 mg per deciliter) compared to those who subsequen-
tly experienced rejection episodes (7.5972.01 mg per deci-
liter). However, significant differences in serum creatinine
values were found at the time of acute rejection (Figure 3).
Urinary output early (week one) and late (week four) post
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Figure 1 | Changes in serum tryptophan, kynurenine, kyn/trp, and neopterin levels in patients during the early post-transplant course.
(a) Kyn/trp, (b) neopterin, and (d) kynurenine levels were higher in the nine patients with acute rejection during the first 21 days after
transplantation (Group II, -&-) than in the 34 patients with an uncomplicated postoperative course (Group I, -B-). (c) Tryptophan
concentrations were significantly lower in Group II than in Group I after 1-week post transplantation. (P-values were determined with use of the
Kruskal–Wallis method).
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transplantation was similar in both groups (19407460 ml vs
18707670 ml and 32807560 ml vs 30507880 ml, respec-
tively). Also, the mean creatinine clearance (Cockcroft and
Gault) in the subjects with/without acute rejection episodes
did not differ significantly (66.4713.4 ml/min as compared
with 52.1720.5 ml/min, P¼ 0.06).
Immunohistochemistry
In order to localize intragraft expression of IDO, all kidney
biopsies (n¼ 10) were stained for IDO by immunohisto-
chemistry. As control, 10 early post-transplant biopsies from
patients with poor graft function owing to acute tubular
necrosis but showing no histopathologic evidence of acute
rejection were selected. Subsequently, all samples were judged
by an independent pathologist who quantitated IDO
expression as the product of the proportion of positive cells
and the staining intensity (see Material and Methods).
Representative images are shown in Figure 4. In biopsies
from the group of patients without rejection, immunostain-
ing for IDO showed only relatively few distinctly positive
areas with a predominantly nuclear staining pattern (Figure
4a). By contrast, biopsies from patients with rejection showed
a substantial number of IDO-positive cells in the mono-
nuclear infiltrates. These IDO-positive cells were morpho-
logically classified as antigen-presenting cells such as
macrophages and dendritic cells. However, strongest IDO
expression was seen in the tubular epithelium with a
very high staining intensity (Figure 4b). In these cells,
staining was predominantly cytoplasmatic (insert Figure 4b).
Interstitial tissue and the vasculature stained negative in
all samples.
IDO expression and enzyme activity in renal epithelial cells
Next, immunostaining for IDO was performed on renal
epithelial cells (A498) following in vitro stimulation with
IFN-g to confirm the main cellular source of IDO during
acute rejection. All cytokine-stimulated cells showed strong
positive cytoplasmic staining for IDO (Figure 4d), whereas
cells without IFN-g-stimulation were negative for IDO
(Figure 4c). These data suggest that during acute rejection,
tubular cells can be induced to express and activate IDO.
DISCUSSION
This study demonstrates that systemic changes in tryptophan
catabolism are associated with local expression and activation
of IDO in the kidney graft of patients during acute rejection
episodes. In addition, the rate of IDO-mediated tryptophan
degradation as expressed by kyn/trp correlates with neopterin
levels. Quantitative changes in kyn/trp and neopterin in
serum and urine thus permit accurate and non-invasive
diagnosis of acute renal allograft rejection.
High serum levels of kyn/trp have been reported in
patients with chronic infection (HIV),21 malignant disease,22
coronary heart disease,23 and neuropsychiatric disorders.24
Furthermore, associations between accelerated tryptophan
catabolism and concentrations of immune stimulation
markers like neopterin, soluble cytokine receptors, or IFN-g
have been described previously.25,26 Although a correlation
does not necessarily confirm a causal relationship, our data
are in line with the assumption that enhanced degradation of
tryptophan and thus lowered tryptophan concentrations are
associated with immune activation pathways. We could
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Figure 2 | Urine levels of kyn/trp and neopterin/creatinine at the
time of an acute rejection episode (black bars) as compared to
levels during an uncomplicated postoperative course (grey bars).
Data are expressed as mean7s.d.
Table 2 | Serum concentrations of tryptophan, kynurenine,
kyn/trp, and neopterin
Group
Tryptophan
(lmol/l)
Kynurenine
(lmol/l)
Kyn/trp
(lmol/mmol)
Neopterin
(nmol/l)
Uncomplicated 41.6711.6a 2.0371.04a 55.1739.6a 46.1743.1a
Rejection 30. 778.29b 3.3271.12c 114.1744.5c 90.9759.1d
Controls 57.277.54 1.3770.44 24.976.24 4.5870.99
kyn/trp, kynurenine to tryptophan ratio.
Data are expressed as mean7s.d. of the individual serum concentrations of
tryptophan, kynurenine, kyn/trp, and neopterin in patients with an uncomplicated
postoperative course (n=34), pooled patients with acute rejection (n=9), and control
individuals (n=30).
aPo0.001 compared to controls.
bP=0.002.
cPo0.001.
dP=0.005 compared to uncomplicated group (Kruskal–Wallis test).
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Figure 3 | Time course of changes in serum creatinine
concentrations in patients with an uncomplicated postoperative
course (Group I, -B-) and patients with acute rejection (Group II,
-&-). Data are expressed as mean7s.d.
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demonstrate that as early as by day one post-transplantation
serum kyn/trp, kynurenine, and neopterin were significantly
elevated in patients who subsequently had an acute rejection
episode as compared with those who had an uncomplicated
course after surgery. In addition, kyn/trp and neopterin were
also significantly increased in urine during renal rejection
and, as shown by immunostaining, IDO was strongly
expressed in the graft during rejection. Accurate diagnosis
of acute rejection still relies on the invasive procedure of
needle biopsy, which can entail various complications and
sampling errors.27,28 Since during acute rejection, lympho-
cytes and macrophages are rapidly activated and release large
amounts of cytokines and other inflammatory mediators
upon activation, an alternative approach to graft biopsy
could be to measure such molecules or their soluble receptors
in biological fluids.29,30 However, despite a multitude of
studies on virtually all cytokines, there are still almost no
convincing data so far on which of the many potential factors
to focus on.31–34
Data of our study suggest that changes of kyn/trp develop
earlier than renal impairment. In the whole dataset, kyn/trp
correlated significantly with creatinine and neopterin con-
centrations. However, kyn/trp already was significantly
different between patients with/without rejections from
post-transplant day one on, whereas the difference of
creatinine levels became significant only around the exact
day of rejection. No difference in creatinine values was
observed between the two groups of patients from the
beginning. The similar chemical nature of amino acids
tryptophan and kynurenine suggests that renal impairment
may influence the two compounds in a similar way. Thus,
one may expect that the direct influence of renal function on
kyn/trp would be minor.
In previous studies neopterin measurement in serum and
urine has been shown to be of clinical value in predicting
immunological complications such as acute rejection in
patients following kidney transplantation.35,36 The current
study shows that the reliability and the advantages of such a
non-invasive approach could be further increased by
simultaneously measuring neopterin and kyn/trp. These
initial observations allow us to hypothesize that changes in
tryptophan metabolism hold the potential for developing a
novel prognostic test for acute rejection of renal allografts.
Analyzing IDO activity immediately after transplantation
could help define the subgroup of patients more likely to
experience acute rejection with additional implications for
immediate implementation of graft-saving therapy. However,
in this regard, further prospective studies with larger patient
numbers, long-term follow-up, and day-to-day analysis of
tryptophan metabolism in conditions that may mimic acute
rejection such as ATN, calcineurin toxicity, and infection will
be necessary to validate our findings.
Holmes et al.37 in a previous report suggested that the
serum abnormalities in oxidative tryptophan metabolism
observed in renal allograft recipients during acute rejection,
infection, and OKT3 therapy reflect a biological response to
IFN-g release in that patient population. However, as far as
the systemic changes in tryptophan and kynurenine owing to
IDO activation are concerned, the cellular source of excessive
IDO production in the graft during renal transplant rejection
has not yet been precisely defined. Beside monocytes and
macrophages, dendritic cells are likely candidates. Indeed,
Munn et al. showed that IDO is expressed in a certain
population of splenic dendritic cells which acquire potent
T-cell regulatory functions as a consequence.38 Upregulation
of IDO has also been reported in monocytes and peripheral
blood mononuclear cells upon mitogen activation or with
IFN-g.39 However, despite a limited number of dendritic cells
and macrophages, our data show intense immunostaining for
IDO mainly in proximal and distal tubuli in patients with
acute rejection episodes, whereas tubular epithelial injury in
the absence of rejection was not associated with increased
IDO expression. The cytoplasmatic and paranuclear pattern
of IDO immunostaining further suggests that during acute
rejection, tubular epithelial cells can be induced to generate
IDO. In addition, our in vitro experiments stimulating renal
epithelial cells with IFN-g also revealed a massive induction
of IDO in these cells, giving further support to the hypothesis
that renal tubuli express functional IDO upon IFN-g
stimulation during acute rejection in vivo. Whether increased
tubular IDO expression downregulates interstitial T-cell
activation via tryptophan deprivation and by proapoptotic
activity of tryptophan metabolites, is open to speculation.
a b
c d
Figure 4 | Immunostaining for IDO. (a) Non-rejected grafts show
almost no IDO expression. Immunostaining revealed relatively few
distinctly positive areas with a predominantly nuclear staining
pattern (score 1.6770.56; see Materials and Methods). (b) In biopsies
from patients with rejection, IDO-positive cells were found in the
mononuclear infiltrates mainly classified as antigen-presenting cells.
Strongest IDO expression was seen in tubular epithelial cells with a
very high staining intensity (score 8.6371.94). In these cells, staining
was predominantly cytoplasmatic (inset in (b)). (c) Unstimulated renal
epithelial cells did not stain for IDO. (d) Following in vitro stimulation
with IFN-g, these cells showed strong positive cytoplasmic IDO
expression. (Original magnifications  250 and  400).
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Furthermore, the question whether IDO enzyme activa-
tion exerts detrimental or beneficial effects during renal
allograft rejection remains to be elucidated. Various experi-
mental studies indicate that the IDO system might be able to
some extent to protect an allograft from immunological
injury. Using a mouse heart transplantation model, we
showed that cardiac allografts are able to express and activate
IDO. Pharmacological inhibition of IDO activity with 1-
methyl tryptophan (1-MT) in recipient animals, however,
resulted in massive and accelerated rejection and graft
survival in the 1-MT-treated animals was significantly
reduced (Brandacher et al. unpublished observation). IDO
inhibition also led to accelerated rejection of murine major
histocompatibility complex class I disparate skin grafts, and
1-MT treatment abrogated tolerance induction of otherwise
spontaneously accepted murine liver grafts.13,40 Recently,
Grohmann et al.41 reported that tolerance induction via
costimulatory blockade was IDO-dependent, as administra-
tion of 1-MT also abrogated the tolerogenic properties of
CTLA4-immunoglobulin in an islet cell transplant model.
Such interactions are of particular interest, since costimula-
tory blockers such as CTLA4-Ig and LEA29Y (belatacept)
represent a new class of primary immunosuppressants that
have shown promising results in human kidney transplanta-
tion.42 By contrast, overexpression of IDO results in
immunosuppression and tolerance. Adenoviral-mediated
IDO gene transfer into pancreatic islet cells prolonged their
survival in allogeneic hosts, and transfection with IDO
protected allogeneic lung transplants from rejection.14,43
These data strongly indicate that IDO activity might have
implications for transplantation biology that reach far
beyond their utilization as a possible diagnostic tool for
acute allograft rejection.
In conclusion, the present study shows that in renal
allograft recipients IDO-mediated tryptophan degradation is
increased before and during allograft rejection and that
measurement of kyn/trp in serum and urine might permit
non-invasive monitoring of renal allograft rejection. Activa-
tion of IDO takes place at highest rates during acute rejection
episodes, but IDO activity, despite otherwise profound
tolerogenic functions, is obviously insufficient to prevent or
counterbalance this alloresponse. Future studies in animal
models are needed to determine the pathophysiologic role of
IDO in solid organ transplantation before it can serve as a
target for therapeutic interventions during acute renal
rejection or potentially for tolerance induction.
MATERIALS AND METHODS
Patients
A total of 43 renal transplant recipients (13 female, 30 male; mean
age7s.d., 52.8713.8 years) were followed prospectively during the
first three postoperative weeks. Immunosuppression consisted of
calcineurin inhibitor-based triple drug therapy with corticosteroids
and mycofenolate mofetil in the majority of cases. Patients were
divided into two groups according to their postoperative course.
Group I (n¼ 34) consisted of patients with an immunologically
uneventful postoperative course. Patients in Group II (n¼ 9)
experienced at least one acute rejection episode within the first
3 weeks; Thirty healthy non-transplanted volunteers served as
controls.
The study was performed in accordance with the ethical
standards laid down in the Declaration of Helsinki Principles and
according to the institutional guidelines at the Department of
General and Transplant Surgery of Innsbruck Medical University.
Informed consent was obtained from all patients and volunteers
participating in this study.
Serum and urine samples from these patients were collected
before, and on days 1, 8, 15, and 21 post-transplantation as well as at
the time of acute rejection. Patients’ basic demographic data and
clinical characteristics are summarized in Table 1.
Blood sampling
Blood samples were collected after an overnight fast and
immediately centrifuged at 4500 g. Serum and urine were stored at
201C until further analysis.
Tryptophan and kynurenine measurement
Tryptophan and kynurenine concentrations in serum and urine were
determined by reversed-phase high-pressure liquid chromatography
as described earlier.20 Briefly, specimens were deproteinized with
trichloroacetic acid and were separated on reversed phase C18
material using 0.015 M potassium phosphate buffer (pH¼ 6.4).
Tryptophan was monitored by means of its native fluorescence at
285 nm excitation and 360 nm emission wavelengths; kynurenine
was detected by UV-absorption at 365 nm wavelength in the same
chromatographic run. Finally, kyn/trp was calculated as an indirect
estimate of IDO activity by dividing kynurenine concentrations
(mmol/l) by tryptophan concentrations (mmol/l). Tryptophan and
kynurenine concentrations were compared to levels determined
earlier in 30 healthy blood donors (15 females and 15 males, aged
20–63 (42.1710.4) years).
Neopterin measurement
Serum and urine neopterin concentrations were analyzed using an
enzyme-linked immunosorbent assay, (BRAHMS Diagnostica
GmbH, Berlin, Germany). The sensitivity was 2 nmol/l neopterin
and the interassay variation coefficient ranged from 4.7 to 8.5%.
Normal serum value provided by the supplier was: mean 5.4 nmol/l
(72.3) with an upper normal limit of 10 nmol/l.
Immunohistochemistry
Immunostaining was performed on paraffin-embedded sections
(4–6 mm) fixed in 10% formalin in phosphate-buffered saline: after
deparaffinization and rehydration, the sections were treated with
0.3%. hydrogen peroxide (and incubated with 10% BSA) to block
nonspecific staining. Incubation with proteinase for 15 min at 371C
was used for antigen-retrieval on the IDO tissue sections. The
primary antibodies were rabbit anti-IDO polyclonal antibodies
(AB5968, Chemicon, Hampshire, UK) and were used at a dilution of
1:300. The sections were incubated with the antibody at 41C
overnight. After washing in Tris-buffered saline, they were incubated
with biotinylated swine anti-rabbit IgG (Dako, Copenhagen,
Denmark) at a dilution of 1:500, and detected with an ABC-
peroxidase-Kit (Vector Laboratories, Burlingame, CA, USA) and
diaminobenzidine as a substrate.
For quantification, the product of proportion of positive cells in
quartiles (0, 1, 2, 3, 4), and the staining intensity (0 no staining;
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1 weak; 2 moderate; 3 strong) was calculated, yielding a total
immunostaining score ranging from 0 to 12.44
Cytospins
A total of 106 A-498 kidney epithelial cells (American Type Culture
Collection, Rockville, MD, USA) were cultured in 3 ml Dulbecco’s
minimal essential medium containing 2 mM L-glutamine, 1 mmol/l
pyruvate, and 10% heat-inactivated fetal calf serum in a humidified
atmosphere containing 5% carbon dioxide at 371C with or without
250 U/ml human recombinant IFN-g (a kind gift of Bioferon Ges.m.
b.H., Laupheim, Germany) for 24 h, detached by trypsinization,
and resuspended in 1 ml of culture medium. Cells were then spun
onto glass slides in a cytospin centrifuge and subsequently
immunostained for IDO.
Statistical analysis
Group comparisons were performed with analysis of variance and
Student’s t-test; Spearman rank correlation coefficients were
calculated because distribution of data was non-Gaussian. Po0.05
was considered to indicate significant differences. All statistical
analyses and tests were performed with the SPSS statistical package
(SPSS 11.0 for windows, Chicago, IL, USA) on a personal computer.
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